24th May 2007 07:03
Oxford Biomedica PLC24 May 2007 For Immediate Release 24 MAY 2007 OXFORD BIOMEDICA TO PRESENT AT 2007 FBR GROWTH CONFERENCE Oxford, UK: 24 May 2007: Oxford BioMedica (LSE: OXB), the leading gene therapycompany, today announces that Nick Woolf, the Company's SVP Corporate Strategy,will give a presentation at the 2007 Friedman Billings Ramsay (FBR) GrowthConference on Thursday, 31 May 2007, at 3.05 PM US Eastern Time (8.05 PM BST).The conference is being held at the Grand Hyatt New York, Park Avenue at GrandCentral, New York. The presentation will be webcast live and may be accessed under the investorssection of the Company's website, www.oxfordbiomedica.co.uk. The presentationwill also be available for replay. -Ends- For further information, please contact:Oxford BioMedica plc: Tel: +44 (0)1865 783 000 Professor Alan Kingsman, Chief ExecutiveCity/Financial Enquiries: Tel: +44 (0)20 7466 5000 Lisa Baderoon/ Mark Court/ Mary-Jane Johnson BuchananCommunicationsScientific/Trade Press Enquiries: Tel: +44 (0)20 7268 3002 Gemma Price/ Holly Griffiths/ Katja StoutNorthbank Communications Notes to editors 1. Oxford BioMedica Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in thedevelopment and commercialisation of novel therapeutic vaccines and gene-basedtherapies with a focus on oncology and neurotherapy. The Company was establishedin 1995 as a spin-out from Oxford University, and is listed on the London StockExchange. The Company has a platform of gene delivery technologies, which are based onhighly engineered viral systems. Oxford BioMedica also has in-house clinical,regulatory and manufacturing know-how. In oncology, the lead product candidateis TroVax(R), an immunotherapy for multiple solid cancers, which is licensed toSanofi-Aventis for global development and commercialisation. A Phase III trialof TroVax in renal cancer is ongoing and Sanofi-Aventis is implementing adevelopment plan for colorectal cancer. Oxford BioMedica's oncology pipelineincludes a specific immunotherapy candidate, Hi-8(R) MEL, for melanoma, whichhas completed two clinical trials. In neurotherapy, the Company's lead product,ProSavin(R), is expected to enter clinical development for Parkinson's diseasein 2007. The neurotherapy pipeline also includes preclinical gene-basedtherapeutics for vision loss, motor neuron disease and nerve repair. Inaddition, the Company has a platform technology for therapeutic vaccines forinfectious diseases. The Company is underpinned by over 80 patent families, which represent one ofthe broadest patent estates in the field. The Company has a staff ofapproximately 75 split between its main facilities in Oxford and its whollyowned subsidiary, BioMedica Inc, in San Diego, California. Corporate partnersinclude Sanofi-Aventis for TroVax and Wyeth for a targeted antibody therapy. TheCompany also has collaborations with Intervet, Sigma-Aldrich, Viragen, MolMedand Virxsys. Technology licensees include Merck & Co, Biogen Idec,GlaxoSmithKline and Pfizer. Further information is available at www.oxfordbiomedica.co.uk This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Oxford Biomedica